The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...
The CHMP has recommended approval of sparsentan for the treatment of primary IgAN – a rare kidney disorder and a leading cause of kidney failure – in adults with a urine protein excretion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback